For your type 2 diabetes patients not at goal*
The Benefits of Empagliflozin + Additional HbA1c Control
Early glycemic control in treating T2D patients
Document ID: PC-PH-101493
23/10/2020
Author: Boehringer Ingelheim
Professor Steven Kahn an Endocrinologist and Director of Diabetes Research Center at the University of Washington discussing his views on the advantages of using an SGLT2 inhibitor and DPP4 inhibitor combination in intensifying treatment for Type 2 Diabetes patients.
Related content
PC-PH-101493
Production date: October 2020
Production date: October 2020
IMPORTANT SAFETY INFORMATION
What important information I should know about Empagliflozin + Linagliptin (Glyxambi®)?
Special warnings and precautions that should be taken into consideration when prescribing Empagliflozin + Linagliptin (Glyxambi®) include:
What are the contraindications to Empagliflozin + Linagliptin (Glyxambi®)?
Empagliflozin + Linagliptin (Glyxambi®) should not be used in patients with type 1 diabetes, patients with severe renal impairment and end stage renal disease, those who have hypersensitivity to Empagliflozin or Linagliptin or any of the excipients.
What should I ask my patients before prescribing Empagliflozin + Linagliptin (Glyxambi®)?
Ask your patients if they are currently taking other medications like the following:
Ask your patients if they are pregnant or planning to be pregnant or are breastfeeding or planning to breastfeed. There are limited data on the use of Empagliflozin + Linagliptin (Glyxambi®) in pregnant women. It is also not known whether the drug is excreted in human milk. As a precautionary measure, it is preferable to avoid the use of Empagliflozin + Linagliptin (Glyxambi®) during pregnancy and breastfeeding.
Special warnings and precautions that should be taken into consideration when prescribing Empagliflozin + Linagliptin (Glyxambi®) include:
- Pancreatitis
- Risk of volume depletion
- Genital mycotic infections
- Diabetic Ketoacidosis
- Complicated urinary tract infections
- Hypoglycemia
- Necrotizing fasciitis
- Allergic (hypersensitivity) reactions
- Hypercholesterolemia
- Arthritis
- Bullous pemphigoid
What are the contraindications to Empagliflozin + Linagliptin (Glyxambi®)?
Empagliflozin + Linagliptin (Glyxambi®) should not be used in patients with type 1 diabetes, patients with severe renal impairment and end stage renal disease, those who have hypersensitivity to Empagliflozin or Linagliptin or any of the excipients.
What should I ask my patients before prescribing Empagliflozin + Linagliptin (Glyxambi®)?
Ask your patients if they are currently taking other medications like the following:
- Insulin and sulphonylureas. These may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or sulphonylureas may be required to reduce the risk of hypoglycaemia when used in combination with Empagliflozin + Linagliptin (Glyxambi®).
- Diuretics. Empagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension.
- UGT inhibitors and inducers. Co-medication with known inducers of UGT enzymes should be avoided because of a risk of decreased efficacy of empagliflozin.
- Rifampin. Co-administration of rifampicin decreased linagliptin exposure by 40%, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-glycoprotein (P-gp) or cytochrome P450 (CYP) isozyme CYP3A4 inducer, particularly if these are administed long-term.
Ask your patients if they are pregnant or planning to be pregnant or are breastfeeding or planning to breastfeed. There are limited data on the use of Empagliflozin + Linagliptin (Glyxambi®) in pregnant women. It is also not known whether the drug is excreted in human milk. As a precautionary measure, it is preferable to avoid the use of Empagliflozin + Linagliptin (Glyxambi®) during pregnancy and breastfeeding.
